E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with modified NYHA functional Class II PAH have mild symptoms, but their pulmonary artery pressures are elevated which leads to increased wall stress and silent heart damage progression. Therefore Class I-II patients have a better survival rate than Class III-IV patients (Odds ratio = 1.9) but will eventually deteriorate if untreated.
|
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate that bosentan improves exercise capacity and/or cardiac hemodynamics in mildly symptomatic PAH patients. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of bosentan on time to clinical worsening, dyspnea, NYHA Class, and quality of life. To demonstrate that bosentan is safe and well tolerated in this patient population. To evaluate the effects of bosentan on hemodynamics and exercise capacity in two groups of mildly symptomatic PAH patients (subgroup analysis), those who are treated with sildenafil at baseline and those who are not on sildenafil treatment at baseline. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
a)Men or women aged 12 years of age and over (except for countries where this age limit is contrary to specific regulatory requirements). Women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception during study treatment and for at least 3 months after study treatment termination. – Reliable method of contraception are: Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide. Intra-uterine devices. Oral, injectable or implantable contraceptives only in combination with a barrier method. – Hormone-based contraceptives alone, regardless of the route of administration, are not considered as reliable methods of contraception. – Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception. Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.
b) PAH in modified NYHA functional class II due to: 1. PAH idiopathic (Primary Pulmonary Hypertension) 2. PAH secondary to human immunodeficiency virus (HIV) 3. PAH secondary to anorexigens 4. PAH secondary to atrial septum defect (ASD) < 2 cm, ventricular septum defect (VSD) < 1 cm or patent ductus arteriosus (PAD) 5. PAH secondary to connective tissue or auto-immune diseases
c) 6-minute walk test (6MWT) distance < 80% of normal predicted value (see Appendix 3 in protocol)
d) Mean pulmonary arterial pressure (mPAP) 25 mmHg and over, pulmonary capillary wedge pressure (PCWP) < 15 mmHg, and pulmonary vascular resistance (PVR) at rest 500 dyn.sec.cm-5 and over
e) Signed informed consent prior to initiation of any study-mandated procedure.
|
|
E.4 | Principal exclusion criteria |
PAH associated with conditions other than those mentioned above, e.g., PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt • Severe obstructive lung disease: FEV1/FVC < 0.5 • Total lung capacity < 80% of normal predicted value • Significant vasoreactivity during right heart catheterization: i.e., a fall in mPAP to < 40 mmHg with a decrease ≥ 10 mmHg and with a normal cardiac index (≥ 2.5 l/min.m2) • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (in particular with 6MWT) • Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements • Symptomatic lower limb vascular disease • HIV patient with opportunistic infection • Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C • AST and/or ALT > 3 times the upper limit of normal ranges. • Hemoglobin concentration < 75% the lower limit of normal ranges • Systolic blood pressure < 85 mmHg • Pregnancy or breast-feeding • Recently started (< 8 weeks prior to randomization) or planned cardio-pulmonary rehabilitation program based on exercise • Treatment or planned treatment with another investigational drug within 3 months of randomization • Treatment with an endothelin receptor antagonist or with prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 3 months of randomization • Treatment for PAH within one month of randomization, excluding sildenafil treatment (if present for at least 2 months before randomization, at a stable dose not lower than 20 mg TID), calcium channel blockers (if present for at least 1 month before randomization) and anticoagulants • Treatment with calcineurin-inhibitors (e.g., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) within 1 week of randomization • Known hypersensitivity to bosentan or any of the excipients • Previous exposure to bosentan |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoints • PVR at rest at EOS expressed as percent of baseline value. geometric mean in the active group showing a reduction least 20% when compared to the placebo geometric mean considered clinically relevant. The natural logarithm of this parameter is expected to be normally distributed with a standard deviation of 0.280 • Change from baseline to End-of-Study (EOS) in 6MWT distance. A mean difference from placebo of at least 35 m considered clinically relevant. This parameter is expected normally distributed with a standard deviation of 65 m |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |